Slide 1: Q2 2023 Financial Results & Business Update
1 Q2 2023 Financial Results & Business Update Nasdaq: OABI August 10, 2023
Slide 2: Disclaimer
2 Disclaimer We caution you that this presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, expected cash runway, business stra
Slide 3: Introduction
Omni > Introduction : Matt Foehr
Slide 4: Our Business
4 Our Business LEVERAGING OUR PROPRIETARY DISCOVERY TECHNOLOGY PLATFORM WORLDWIDE Technology Offering Addresses Most One of the Largest Greenfields Critical Challenges of Discovery in the Pharma Industry Create, Screen, Deliver antibodies leveraging $279 billion total addressable market industry’s o
Slide 5: Mission
Our mission is to enable the rapid Mission development of innovative therapeutics by pushing the frontiers of drug discovery technologies.
Slide 6: Active Partners
6 Active Partners Q2 2023: 74 ACTIVE PARTNERS Number of Active Partners 80 • 4 new license agreements signed in Q2 70 ‒ New platform license agreements with Merck & Co. Inc., 60 Neurocrine Biosciences Inc., Stanford University, and Seattle 50 Children’s Hospital 40 30 • Strong annual growth in Activ
Slide 7: Select OmniAb Partners
7 Select OmniAb Partners >70 COMPANIES CURRENTLY HAVE ACCESS TO OMNIAB ANTIBODIES
Slide 8: Active Programs
8 Active Programs GROWTH AND PROGRESSION CONTINUES Number of Active Programs 305 Active Programs as of 06/30/2023 350 • Number of Active Programs 300 reached 305 (net of discovery- Phase 2: 2 Phase 3: 1 stage attrition) BLA: 1 250 Phase 1: 22 ‒ Active Programs: ̴ 25% Approved: 3 200 CAGR 2016 throug
Slide 9: Active Clinical Programs and Approved Products
9 Active Clinical Programs and Approved Products TWO NEW CLINICAL ENTRANTS IN Q2 2023 Number of Active Clinical Programs and Approved Products • 2 new programs entered the clinic in Q2 ‒ IMVT-1402 (Immunovant): Next-generation FcRn antagonist 30 ‒ GLS-012 (Gloria): anti-LAG-3 25 • 3 new programs hav
Slide 10: Q2 2023 and Recent Updates
10 Q2 2023 and Recent Updates SELECT RECENT DEVELOPMENTS SHOW CONTINUED PARTNER MOMENTUM Batoclimab IMVT-1402 CSX-1004 APVO436 GSK Program-1 FcRn FcRn Anti-fentanyl CD123 x CD3 Ion Channels and (and related synthetic opioids) Transporters • Immunovant is conducting • Immunovant initiated a • Cessati
Slide 11: Ion Channels and Transporters
11 Ion Channels and Transporters Ions • Ion channels are key components in Ions Outside of cell a wide variety of biological processes that involve rapid changes in cells • Present in all human cells and affect vital functions such as nerve transmission, muscle contraction, cellular secretory proces
Slide 12: Ion Channels and Transporters
12 Ion Channels and Transporters DIFFERENTIATED ION CHANNELS AND TRANSPORTERS DISCOVERY PLATFORM AT OMNIAB • One of industry’s most experienced teams of ion channel discovery experts Collaborations for High-Value Targets • Continuous expansion and development of cutting-edge technologies including h
Slide 13: Our Key Areas of Focus Going Forward
13 Our Key Areas of Focus Going Forward WE BELIEVE WE ARE WELL-POSITIONED FOR FUTURE GROWTH WHILE WE MAKE AN ENDURING AND SIGNIFICANT IMPACT ON THE INDUSTRY AND GLOBAL HUMAN HEALTH We Leverage a Highly Scalable Business where Investments in Technologies and Innovation are Informed by Discovery Relat
Slide 14: Financial Updates
14 Financial Updates Kurt Gustafson
Slide 15: Q2 2023 vs. Q2 2022 Financial Results
15 Q2 2023 vs. Q2 2022 Financial Results Table includes rounded figures. Please reference press release dated 8.10.2023 for more detailed information.
Slide 16: Balance Sheet - June '23 vs. December '22
16 Balance Sheet - June ‘23 vs. December ‘22 Business is close to break-even cash flow Expect to end 2023 with slightly more cash than 12/31/22 cash balance Current cash balance and cash from operations expected to provide sufficient capital to fund operations for foreseeable future
Slide 17: Quarterly Results
17 Quarterly Results ($ Millions) Q1 '22 Q2 '22 Q3 '22 Q4 '22 Q1 '23 Q2 '23 License and milestone revenue $ 4.1 $ 2.3 $ 1.4 $ 31.1 $ 12.6 $ 4.3 Service revenue 5.3 4.7 4.9 3.9 4.0 2.5 Royalty revenue 0.3 0.1 0.6 0.4 0.3 0.2 Total revenues 9.6 7.2 6.9 35.3 16.9 6.9 Research & development 10.8 11.5 13
Slide 18: Q&A
Omni Q&A
Slide 19: Approved, Under Regulatory Review and Clinical-Stage Partner Pipeline
19 Approved, Under Regulatory Review and Clinical-Stage Partner Pipeline AS OF 06/30/2023 Partner Program Source Animal Therapy Area Target Phase 1 Phase 2 Phase 3 Registration Approved Zimberelimab OmniRat Oncology PD-1 Sugemalimab OmniRat Oncology PD-L1 Teclistamab OmniRat Oncology BCMA x CD3 Bato
Slide 20: Omni >
Omni >